
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4936450/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. Journal of Clinical Oncology, 2022, 40, 1741-1754.	1.6	65
2	Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria. Cell Host and Microbe, 2022, 30, 1020-1033.e6.	11.0	37
3	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF- $\hat{1}^2$ blockade in HPV-unrelated head and neck cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	18
4	Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging. Journal of Endocrinological Investigation, 2021, 44, 1475-1482.	3.3	7
5	First Somatic <i>PRKAR1A</i> Defect Associated With Mosaicism for Another <i>PRKAR1A</i> Mutation in a Patient With Cushing Syndrome. Journal of the Endocrine Society, 2021, 5, bvab007.	0.2	3
6	Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science, 2021, 371, .	12.6	84
7	Miliary fibromas in tuberous sclerosis complex. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1226-1229.	2.4	4
8	Host-Pathogen Interactions in Human Polyomavirus 7‒Associated Pruritic Skin Eruption. Journal of Investigative Dermatology, 2021, 141, 1344-1348.e8.	0.7	7
9	Histopathological features of fibrous cephalic plaques in tuberous sclerosis complex. Histopathology, 2021, 79, 619-628.	2.9	3
10	Response to Comments on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections― Science, 2021, 373, eabi8835.	12.6	5
11	GATA-2–deficient mast cells limit IgE-mediated immediate hypersensitivity reactions in human subjects. Journal of Allergy and Clinical Immunology, 2019, 144, 613-617.e14.	2.9	21
12	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Science Translational Medicine, 2019, 11, .	12.4	52
13	Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition ofÂGamma-Secretase. Journal of Investigative Dermatology, 2018, 138, 979-981.	0.7	14
14	Chromogranin A is not a biomarker of mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 687-689.e4.	3.8	8
15	Pharmacological Blockade of the Chemokine Receptor CCR1 Protects Mice from Systemic Candidiasis of Hematogenous Origin. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
16	Host immune status-specific production of gliotoxin and bis-methyl-gliotoxin during invasive aspergillosis in mice. Scientific Reports, 2017, 7, 10977.	3.3	14
17	Vibratory Urticaria Associated with a Missense Variant in <i>ADGRE2</i> . New England Journal of Medicine, 2016, 374, 656-663.	27.0	157
18	Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology, 2016, 86, 847-855.	1.1	36

#	Article	IF	CITATIONS
19	ldentification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clinical Cancer Research, 2016, 22, 2237-2249.	7.0	71
20	Immunophenotypic and Ultrastructural Analysis of Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection to Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0159177.	2.5	15
21	Isolated Large Cell Calcifying Sertoli Cell Tumor in a Young Boy, not Associated with Peutz-Jeghers Syndrome or Carney Complex. Annals of Clinical and Laboratory Research, 2015, 3, 2.	0.1	6
22	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research, 2015, 21, 1019-1027.	7.0	677
23	Recurrent Mutations in the Basic Domain of TWIST2 Cause Ablepharon Macrostomia and Barber-Say Syndromes. American Journal of Human Genetics, 2015, 97, 99-110.	6.2	61
24	Assessment of Cancer Cell Line Representativeness Using Microarrays for Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2015, 135, 1138-1146.	0.7	38
25	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. Cancer Immunology Research, 2015, 3, 37-47.	3.4	24
26	New facial papules in a 66-year-old woman with bladder cancer. Journal of the American Academy of Dermatology, 2014, 71, 1250-1255.	1.2	3
27	Cutaneous metastasis of prostate cancer: a case report and review of the literature with bioinformatics analysis of multiple healthcare delivery networks. Journal of Cutaneous Pathology, 2014, 41, 524-528.	1.3	22
28	Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy. Clinical Cancer Research, 2014, 20, 331-343.	7.0	55
29	Recurrent erythematous plaques on sun-exposed sites in an African American boy with chronic granulomatous disease. Journal of the American Academy of Dermatology, 2014, 70, 576-580.	1.2	6
30	The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathologica Communications, 2013, 1, 4.	5.2	40
31	Diabetes insipidus, bone lesions, and new-onset red-brown papules in a 42-year-old man. Journal of the American Academy of Dermatology, 2013, 68, 1034-1038.	1.2	1
32	A unique pattern of INI1 immunohistochemistry distinguishes synovial sarcoma from its histologic mimics. Human Pathology, 2013, 44, 881-887.	2.0	48
33	Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. Journal of Experimental Medicine, 2013, 210, 1125-1135.	8.5	321
34	Zoon's balanitis with mucinous metaplasia: A case report and review of literature. Open Journal of Clinical Diagnostics, 2013, 03, 33-36.	0.3	1
35	Fluorescence In Situ Hybridization Study of Chromosome Abnormalities of Upper Urinary Tract Urothelial Carcinoma in Paraffin-Embedded Tissue. American Journal of Clinical Pathology, 2012, 138, 382-389.	0.7	6
36	Chemokine Receptor Ccr1 Drives Neutrophil-Mediated Kidney Immunopathology and Mortality in Invasive Candidiasis. PLoS Pathogens, 2012, 8, e1002865.	4.7	102

#	Article	IF	CITATIONS
37	NY-ESO-1 expression in sarcomas. Oncolmmunology, 2012, 1, 1409-1410.	4.6	41
38	The Stoichiometric Production of IL-2 and IFN-Î ³ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans. Science Translational Medicine, 2012, 4, 149ra120.	12.4	51
39	NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Modern Pathology, 2012, 25, 854-858.	5.5	102
40	Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase–deficient severe combined immune deficiency. Journal of Allergy and Clinical Immunology, 2012, 129, 762-769.e1.	2.9	64
41	Myxoma of the ear lobe in a 23â€monthâ€old girl with Carney complex. Journal of Cutaneous Pathology, 2012, 39, 68-71.	1.3	4
42	Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of <i>NF1</i> in neurofibromatosis type 1â€associated glomus tumors. Genes Chromosomes and Cancer, 2012, 51, 429-437.	2.8	27
43	Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis and Rheumatism, 2012, 64, 895-907.	6.7	340
44	Homeostatic Tissue Responses in Skin Biopsies from NOMID Patients with Constitutive Overproduction of IL-1β. PLoS ONE, 2012, 7, e49408.	2.5	36
45	Histologic variants of periungual fibromas in tuberous sclerosis complex. Journal of the American Academy of Dermatology, 2011, 64, 442-444.	1.2	15
46	Bilateral Areolar Lesions in a Patient With Acute Cutaneous Graft-vs-Host Disease. Archives of Dermatology, 2011, 147, 509.	1.4	2
47	Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology, 2011, 29, 917-924.	1.6	1,427
48	Organ-Specific Innate Immune Responses in a Mouse Model of Invasive Candidiasis. Journal of Innate Immunity, 2011, 3, 180-199.	3.8	252
49	Genetic Diversity in Melanoma Metastases from a Patient with Xeroderma Pigmentosum. Journal of Investigative Dermatology, 2010, 130, 1188-1191.	0.7	7
50	Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1. Journal of Medical Genetics, 2010, 47, 525-532.	3.2	61
51	Acute patchy exanthematous pustulosis caused by sulfamethoxazole-trimethoprim. Journal of the American Academy of Dermatology, 2010, 63, e41-e43.	1.2	12
52	Successful treatment of periodontal mucormycosis: report of a case and literature review. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 109, e64-e69.	1.4	44
53	CCR6 is required for IL-23–induced psoriasis-like inflammation in mice. Journal of Clinical Investigation, 2009, 119, 2317-2329.	8.2	207
54	Glomus Tumors in Neurofibromatosis Type 1: Genetic, Functional, and Clinical Evidence of a Novel Association. Cancer Research, 2009, 69, 7393-7401.	0.9	122

#	Article	IF	CITATIONS
55	Matriptase-Deficient Mice Exhibit Ichthyotic Skin with a Selective Shift in Skin Microbiota. Journal of Investigative Dermatology, 2009, 129, 2435-2442.	0.7	60
56	Autosomal Dominant Epidermodysplasia Verruciformis Lacking a Known EVER1 or EVER2 Mutation. Pediatric Dermatology, 2009, 26, 306-310.	0.9	40
57	A Sri Lankan woman with rheumatoid arthritis and anesthetic plaques. Journal of the American Academy of Dermatology, 2009, 60, 1018-1021.	1.2	2
58	An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist. New England Journal of Medicine, 2009, 360, 2426-2437.	27.0	892
59	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009, 114, 535-546.	1.4	1,280
60	p53Status in Multiple Human Urothelial Cancers: Assessment for Clonality by the Yeast p53 Functional Assay in Combination with p53 Immunohistochemistry. Japanese Journal of Cancer Research, 2000, 91, 181-189.	1.7	10
61	Loss of Heterozygosity Assay for Molecular Detection of Cancer Using Energy-transfer Primers and Capillary Array Electrophoresis. Genome Research, 2000, 10, 1211-1218.	5.5	49
62	Reduced expression of the CDK inhibitor p27KIP1 in rat two-stage bladder carcinogenesis and its association with expression profiles of p21WAF1/Cip1 and p53. Carcinogenesis, 1999, 20, 1697-1708.	2.8	11
63	Urinary Bladder Lesions after the Chernobyl Accident: Immunohistochemical Assessment of p53, Proliferating Cell Nuclear Antigen, Cyclin D1 and p21WAF1/Cip1. Japanese Journal of Cancer Research, 1999, 90, 144-153.	1.7	15
64	Loss of Heterozygosity in (Lewis×F344)F1Rat Urinary Bladder Tumors Induced with N-Butyl-N-(4-hydroxybutyl)nitrosamine Followed by Dimethylarsinic Acid or Sodium L-Ascorbate. Japanese Journal of Cancer Research, 1999, 90, 818-823.	1.7	4
65	Molecular cytogenetic identification of cyclin D1 gene amplification in a renal pelvic tumor attributed to phenacetin abuse. Pathology International, 1999, 49, 648-652.	1.3	1
66	Enhancement of urinary bladder carcinogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Letters, 1999, 135, 137-144.	7.2	12
67	Review article Alterations in cyclin D1, p53, and the cell cycle related elements. Urologic Oncology: Seminars and Original Investigations, 1998, 4, 58-72.	1.6	6
68	Assessment of Cell Cycle-related Elements p53, p21WAF1/Cip1, Cyclin D1 and PCNA in a Mixed Transitional Cell Carcinoma and Adenocarcinoma of the Renal Pelvis: a Case Report. Japanese Journal of Clinical Oncology, 1998, 28, 227-232.	1.3	4
69	Reversibility and apoptosis in rat urinary bladder papillomatosis induced by uracil. Carcinogenesis, 1997, 18, 1485-1489.	2.8	21
70	Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. , 1997, 79, 780-789.		88